Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile

K. J. Woodside, S. D. Nichols, G. C. Hunter, Kristene Gugliuzza, J. A. Daller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction. While cyclosporine and tacrolimus use results in similar renal graft survival, the side effect profiles of the drugs are substantially different. We examined the electrolyte and lipid alterations that occurred in our patient population following conversion from cyclosporine to tacrolimus. Methods. Data for electrolytes, lipid profile, and immunosuppression were analyzed from 98 patients with kidney or kidney-pancreas transplants who were converted from cyclosporine to tacrolimus between October 1994 and June 2001. Results, expressed as mean ± SEM, were compared to baseline values using the Wilcoxon signed-rank test (P <. 05 considered significant). Results. Among these patients, there were 56 men, 42 women, 75 primary transplants, 15 repeat transplants, and 26 multiorgan transplants. The mean time to tacrolimus conversion was 769 ± 122 days. Creatinine, BUN, and glucose improved after conversion to tacrolimus. Surprisingly, cholesterol, low-density lipoproteins, and high-density lipoproteins levels were not significantly altered, although triglyceride levels demonstrated a significant difference at 1 year. Conclusion. Significant improvements in creatinine and BUN were observed following conversion from cyclosporine to tacrolimus. While hypomagnesemia was also seen, there was surprisingly little alteration in lipid profile.

Original languageEnglish (US)
Pages (from-to)1877-1879
Number of pages3
JournalTransplantation Proceedings
Volume37
Issue number4
DOIs
StatePublished - May 2005

Fingerprint

Tacrolimus
Cyclosporine
Creatinine
Lipids
Transplants
Blood Urea Nitrogen
Kidney
Electrolytes
Graft Survival
HDL Lipoproteins
Nonparametric Statistics
Drug-Related Side Effects and Adverse Reactions
LDL Cholesterol
Immunosuppression
Pancreas
Triglycerides
Glucose
Population

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. / Woodside, K. J.; Nichols, S. D.; Hunter, G. C.; Gugliuzza, Kristene; Daller, J. A.

In: Transplantation Proceedings, Vol. 37, No. 4, 05.2005, p. 1877-1879.

Research output: Contribution to journalArticle

Woodside, K. J. ; Nichols, S. D. ; Hunter, G. C. ; Gugliuzza, Kristene ; Daller, J. A. / Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. In: Transplantation Proceedings. 2005 ; Vol. 37, No. 4. pp. 1877-1879.
@article{297feb6aeea84c86a8536570f46969d0,
title = "Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile",
abstract = "Introduction. While cyclosporine and tacrolimus use results in similar renal graft survival, the side effect profiles of the drugs are substantially different. We examined the electrolyte and lipid alterations that occurred in our patient population following conversion from cyclosporine to tacrolimus. Methods. Data for electrolytes, lipid profile, and immunosuppression were analyzed from 98 patients with kidney or kidney-pancreas transplants who were converted from cyclosporine to tacrolimus between October 1994 and June 2001. Results, expressed as mean ± SEM, were compared to baseline values using the Wilcoxon signed-rank test (P <. 05 considered significant). Results. Among these patients, there were 56 men, 42 women, 75 primary transplants, 15 repeat transplants, and 26 multiorgan transplants. The mean time to tacrolimus conversion was 769 ± 122 days. Creatinine, BUN, and glucose improved after conversion to tacrolimus. Surprisingly, cholesterol, low-density lipoproteins, and high-density lipoproteins levels were not significantly altered, although triglyceride levels demonstrated a significant difference at 1 year. Conclusion. Significant improvements in creatinine and BUN were observed following conversion from cyclosporine to tacrolimus. While hypomagnesemia was also seen, there was surprisingly little alteration in lipid profile.",
author = "Woodside, {K. J.} and Nichols, {S. D.} and Hunter, {G. C.} and Kristene Gugliuzza and Daller, {J. A.}",
year = "2005",
month = "5",
doi = "10.1016/j.transproceed.2005.02.095",
language = "English (US)",
volume = "37",
pages = "1877--1879",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile

AU - Woodside, K. J.

AU - Nichols, S. D.

AU - Hunter, G. C.

AU - Gugliuzza, Kristene

AU - Daller, J. A.

PY - 2005/5

Y1 - 2005/5

N2 - Introduction. While cyclosporine and tacrolimus use results in similar renal graft survival, the side effect profiles of the drugs are substantially different. We examined the electrolyte and lipid alterations that occurred in our patient population following conversion from cyclosporine to tacrolimus. Methods. Data for electrolytes, lipid profile, and immunosuppression were analyzed from 98 patients with kidney or kidney-pancreas transplants who were converted from cyclosporine to tacrolimus between October 1994 and June 2001. Results, expressed as mean ± SEM, were compared to baseline values using the Wilcoxon signed-rank test (P <. 05 considered significant). Results. Among these patients, there were 56 men, 42 women, 75 primary transplants, 15 repeat transplants, and 26 multiorgan transplants. The mean time to tacrolimus conversion was 769 ± 122 days. Creatinine, BUN, and glucose improved after conversion to tacrolimus. Surprisingly, cholesterol, low-density lipoproteins, and high-density lipoproteins levels were not significantly altered, although triglyceride levels demonstrated a significant difference at 1 year. Conclusion. Significant improvements in creatinine and BUN were observed following conversion from cyclosporine to tacrolimus. While hypomagnesemia was also seen, there was surprisingly little alteration in lipid profile.

AB - Introduction. While cyclosporine and tacrolimus use results in similar renal graft survival, the side effect profiles of the drugs are substantially different. We examined the electrolyte and lipid alterations that occurred in our patient population following conversion from cyclosporine to tacrolimus. Methods. Data for electrolytes, lipid profile, and immunosuppression were analyzed from 98 patients with kidney or kidney-pancreas transplants who were converted from cyclosporine to tacrolimus between October 1994 and June 2001. Results, expressed as mean ± SEM, were compared to baseline values using the Wilcoxon signed-rank test (P <. 05 considered significant). Results. Among these patients, there were 56 men, 42 women, 75 primary transplants, 15 repeat transplants, and 26 multiorgan transplants. The mean time to tacrolimus conversion was 769 ± 122 days. Creatinine, BUN, and glucose improved after conversion to tacrolimus. Surprisingly, cholesterol, low-density lipoproteins, and high-density lipoproteins levels were not significantly altered, although triglyceride levels demonstrated a significant difference at 1 year. Conclusion. Significant improvements in creatinine and BUN were observed following conversion from cyclosporine to tacrolimus. While hypomagnesemia was also seen, there was surprisingly little alteration in lipid profile.

UR - http://www.scopus.com/inward/record.url?scp=20344373434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344373434&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2005.02.095

DO - 10.1016/j.transproceed.2005.02.095

M3 - Article

C2 - 15919491

AN - SCOPUS:20344373434

VL - 37

SP - 1877

EP - 1879

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -